TAVI: Study shows 80% survival at 2 years for Direct Flow device

Direct Flow Medical says 2-year data from its Discover CE Mark trial showed an 80% survival rate at 2 years for its transcatheter aortic valve implant.

Direct Flow Medical today said data from a clinical trial of its replacement heart valve showed an 80% survival rate after 2 years.

Direct Flow Medical Inc.

News Well, Clinical Trials, Replacement Heart Valves

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1IJnr8T